Patents by Inventor Yi-Rang KIM

Yi-Rang KIM has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240197695
    Abstract: The present disclosure relates to a use of (R)-4-{(R)-1-[7-(3,4,5-trimethoxy-phenyl)-[1,6] naphthyridin-5-yloxy]-ethyl}pyrrolidin-2-one in treating kidney disease. According to the present disclosure, (R)-4-{(R)-1-[7-(3,4,5-trimethoxy-phenyl)-[1,6] naphthyridin-5-yloxy]-ethyl}pyrrolidin-2-one of the present disclosure palliates clinical symptoms and alleviates renal failure and renal injury through reduction of blood glucose levels and insulin resistance in diabetic nephrosis animal models. Thus, the compound may be advantageously applied to a use for preventing or treating kidney diseases, especially diabetic renal diseases.
    Type: Application
    Filed: March 31, 2022
    Publication date: June 20, 2024
    Applicant: ONCOCROSS CO.,LTD
    Inventor: Yi Rang KIM
  • Patent number: 11973209
    Abstract: A positive electrode active material for a secondary battery includes a lithium composite transition metal oxide including nickel (Ni), cobalt (Co), and manganese (Mn), wherein the lithium composite transition metal oxide has a layered crystal structure of space group R3m, includes the nickel (Ni) in an amount of 60 mol % or less based on a total amount of transition metals, includes the cobalt (Co) in an amount greater than an amount of the manganese (Mn), and is composed of single particles.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: April 30, 2024
    Assignee: LG Chem, Ltd.
    Inventors: Eun Hee Lee, Seong Bae Kim, Young Su Park, Yi Rang Lim, Hong Kyu Park, Song Yi Yang, Byung Hyun Hwang, Woo Hyun Kim
  • Patent number: 11973222
    Abstract: A positive electrode active material precursor having a uniform particle size distribution and represented by Formula 1, wherein a percentage of fine powder with an average particle diameter (D50) of 1 ?m or less is generated when the positive electrode active material precursor is rolled at 2.5 kgf/cm2 is less than 1%, and an aspect ratio is 0.93 or more, and a method of preparing the positive electrode active material precursor [NixCoyM1zM2w](OH)2 ??[Formula 1] in Formula 1, 0.5?x<1, 0<y?0.5, 0<z?0.5, and 0?w?0.1, M1 includes at least one selected from the group consisting of Mn and Al, and M2 includes at least one selected from the group consisting of Zr, B, W, Mo, Cr, Nb, Mg, Hf, Ta, La, Ti, Sr, Ba, Ce, F, P, S, and Y. A method of preparing the positive electrode active material precursor is also provided.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: April 30, 2024
    Assignee: LG Chem, Ltd.
    Inventors: Seong Bae Kim, Yi Rang Lim, Kyoung Wan Park, Hyun Uk Kim, Hong Kyu Park, Chang Jun Moon, Eun Hee Kim
  • Publication number: 20240108611
    Abstract: The present invention relates to a composition for the treatment of metabolic diseases, containing torsemide and cromolyn. According to the present invention, if torsemide and cromolyn are used in combination, compared to when cromolyn alone is used, weight is reduced, insulin resistance is reduced and liver fat accumulation is remarkably reduced in a NASH animal model, and thus the present invention can be effectively used in the prevention or treatment of metabolic diseases including diabetes, obesity, insulin resistance and metabolic liver diseases.
    Type: Application
    Filed: February 7, 2022
    Publication date: April 4, 2024
    Applicant: ONCOCROSS CO., LTD.
    Inventor: Yi-Rang KIM
  • Publication number: 20240062851
    Abstract: A method for diagnosing cancer of unknown primary site by using artificial intelligence is disclosed. A method for diagnosing cancer of unknown primary site by using artificial intelligence, according to one embodiment of the present invention, includes the steps of: generating gene expression pattern information of a sample collected from tissue in which metastatic cancer has occurred; removing gene expression pattern information derived from pre-learned tissue from the gene expression pattern information of the sample collected from the tissue in which the metastatic cancer has occurred; comparing the gene expression pattern information from which the gene expression pattern information derived from the tissue has been removed with pre-learned gene expression pattern information for each cancer type; and specifying a primary site of the sample collected from the tissue in which the metastatic cancer has occurred.
    Type: Application
    Filed: September 22, 2022
    Publication date: February 22, 2024
    Inventors: Young Heun LEE, Yi Rang KIM, Ji Hoon KANG
  • Publication number: 20230402130
    Abstract: A method, a device, and a computer program for predicting the interaction between a compound and a protein are provided. A method for predicting the interaction between a compound and a protein, according to some embodiments of the present disclosure, may include: acquiring compound data for training, protein data for training, and training data including interaction scores; constructing a deep-learning model by using the acquired training data; and predicting the interaction between the given compound and protein by using the constructed deep-learning model. The interaction between the given compound and protein in an in vivo environment can be accurately predicted by training the deep-learning model, while excluding, from an amino acid sequence of the protein for training, amino acid sequences associated with a protein domain having a negative influence on the interaction.
    Type: Application
    Filed: December 6, 2021
    Publication date: December 14, 2023
    Applicant: ONCOCROSS CO., LTD.
    Inventors: Jin Woo CHOI, Yi Rang KIM
  • Publication number: 20230301953
    Abstract: The present invention relates to a pharmaceutical composition comprising calcium pantothenate, or calcium pantothenate and dimenhydrinate as active ingredients for prevention and treatment of myopathy. According to the present disclosure, calcium pantothenate upregulates the expression of MHC, myogenin 4-EBP, and p70S6K to promote myoblast differentiation and myogenesis, thereby prolonging the duration of life in amyotrophic lateral sclerosis patients and promoting the growth of MSC in Duchenne muscular dystrophy mice. Such effects are synergistically increased upon combined treatment with dimenhydrinate. Thus, they can be advantageously used for preventing or treating myopathy.
    Type: Application
    Filed: August 10, 2021
    Publication date: September 28, 2023
    Applicant: ONCOCROSS CO.,LTD.
    Inventor: Yi-Rang KIM
  • Publication number: 20230063188
    Abstract: Provided are a method, an apparatus, and a computer program for predicting interaction between a compound and a protein. A method for predicting interaction between a compound and a protein according to some embodiments of the present disclosure may comprises the steps of: acquiring learning data composed of compound data for learning, protein data for learning, and interaction scores; constructing a deep-learning model by using the acquired learning data; and predicting interaction of a given compound and protein through the constructed deep-learning model. Through the learning of the deep-learning mode with the exclusion of amino acid sequences associated with protein domains having a negative influence on interactions from amino acid sequences of proteins for learning, the interaction between a given compound and protein in the in vivo environment can be accurately predicted.
    Type: Application
    Filed: December 14, 2020
    Publication date: March 2, 2023
    Inventors: Jin Woo CHOI, Yi Rang KIM
  • Publication number: 20230042132
    Abstract: A disease prediction method, apparatus, and computer program are provided. A disease prediction method according to several embodiments of the present disclosure can comprise the steps of: constructing a disease prediction model by learning learning data including ribosome data and disease information for learning, acquiring test ribosome data of an examinee; and predicting disease information about the examinee form the test ribosome data by using the disease prediction model. The disease prediction model can accurately predict disease information about the examinee by detecting and learning the characteristics of ribosome data, which vary according to disease information.
    Type: Application
    Filed: December 14, 2020
    Publication date: February 9, 2023
    Inventors: Jin Woo CHOI, Yi Rang KIM
  • Publication number: 20220273642
    Abstract: The present disclosure relates to an effect of inhibiting cancer metastasis by treatment of chlorphenesin and hydroxychloroquine alone or in combination. Chlorphenesin or hydroxychloroquine has the effect of inhibiting the metastasis and invasion of cancer cells. In particular, since it was identified that a combination thereof has a synergistic action, it is possible to effectively prevent or treat cancer metastasis by administering chlorphenesin and hydroxychloroquine respectively or in combination thereof.
    Type: Application
    Filed: May 11, 2022
    Publication date: September 1, 2022
    Applicant: ONCOCROSS CO., LTD.
    Inventors: Yi-Rang Kim, Sang Yun Park, Ga Eul Yang, Seung Jun Lee
  • Publication number: 20220265663
    Abstract: The present invention relates to a pharmaceutical composition for prevention or treatment of a muscular disease, the composition comprising dimenhydrinate, harmol and/or calcium pantothenate as active ingredients. Application of dimenhydrinate, harmol, and calcium pantothenate individually has an effect of promoting myoblast proliferation and differentiation. In particular, the combination thereof has the effect of synergistically increasing the effect of promoting myoblast proliferation and differentiation. Thus, dimenhydrinate, harmol and/or calcium pantothenate may be usefully used alone or in combination for the prevention or treatment of muscular diseases, in particular sarcopenia.
    Type: Application
    Filed: May 13, 2022
    Publication date: August 25, 2022
    Inventors: Yi-Rang KIM, Jin-Woo CHOI
  • Patent number: 11364237
    Abstract: The present invention relates to an anticancer and metastasis inhibiting effect by treatment with chlorphenesin, chloroquine, and chloropyrazine alone or in combination. Chlorphenesin, chloroquine, or chloropyrazine show the effect of killing cancer cells and inhibiting proliferation, and metastasis of cancer cells and particularly, a combination thereof is identified to have synergism. Cancer can be effectively prevented or treated by administering chlorphenesin, chloroquine, and chloropyrazine alone or in combination thereof.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: June 21, 2022
    Assignee: ONCOCROSS CO., LTD.
    Inventor: Yi-Rang Kim
  • Patent number: 11364244
    Abstract: The present invention relates to a pharmaceutical composition for prevention or treatment of a muscular disease, the composition comprising dimenhydrinate, harmol and/or calcium pantothenate as active ingredients. Application of dimenhydrinate, harmol, and calcium pantothenate individually has an effect of promoting myoblast proliferation and differentiation. In particular, the combination thereof has the effect of synergistically increasing the effect of promoting myoblast proliferation and differentiation. Thus, dimenhydrinate, harmol and/or calcium pantothenate may be usefully used alone or in combination for the prevention or treatment of muscular diseases, in particular sarcopenia.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: June 21, 2022
    Assignee: ONCOCROSS CO., LTD.
    Inventors: Yi-Rang Kim, Jin-Woo Choi
  • Publication number: 20200246343
    Abstract: The present invention relates to a pharmaceutical composition for prevention or treatment of a muscular disease, the composition comprising dimenhydrinate, harmol and/or calcium pantothenate as active ingredients. Application of dimenhydrinate, harmol, and calcium pantothenate individually has an effect of promoting myoblast proliferation and differentiation. In particular, the combination thereof has the effect of synergistically increasing the effect of promoting myoblast proliferation and differentiation. Thus, dimenhydrinate, harmol and/or calcium pantothenate may be usefully used alone or in combination for the prevention or treatment of muscular diseases, in particular sarcopenia.
    Type: Application
    Filed: April 17, 2019
    Publication date: August 6, 2020
    Applicant: ONCOCROSS CO., LTD.
    Inventors: Yi-Rang KIM, Jin-Woo CHOI
  • Publication number: 20190374538
    Abstract: The present invention relates to an anticancer and metastasis inhibiting effect by treatment with chlorphenesin, chloroquine, and chloropyrazine alone or in combination. Chlorphenesin, chloroquine, or chloropyrazine show the effect of killing cancer cells and inhibiting proliferation, and metastasis of cancer cells and particularly, a combination thereof is identified to have synergism. Cancer can be effectively prevented or treated by administering chlorphenesin, chloroquine, and chloropyrazine alone or in combination thereof.
    Type: Application
    Filed: February 6, 2018
    Publication date: December 12, 2019
    Applicant: ONCOCROSS CO., LTD.
    Inventor: Yi-Rang KIM